Halozyme Therapeutics Inc. (HALO) Financials Nov 2
Post# of 250666
Posted On: 11/20/2014 8:44:16 PM
Halozyme Therapeutics Inc. (HALO) Financials Nov 20, 2014, 5:14 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Halozyme Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 13.67M 13.62M 56.09M 42.33M 54.8M
Cost of Goods Sold (COGS) incl. D&A 1.76M 2.49M 1.35M 2.17M 7.47M
COGS excluding D&A 311,891 985,283 257,834 1.09M 6.25M
Depreciation & Amortization Expense 1.44M 1.51M 1.1M 1.08M 1.23M
Depreciation 1.44M 1.51M 1.1M 1.08M 1.23M
Amortization of Intangibles - 0 0 0 0
Gross Income 11.92M 11.13M 54.73M 40.15M 47.33M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 69.53M 63.27M 74.57M 93.78M 127.76M
Research & Development 56.61M 50.57M 57.56M 68.96M 95.41M
Other SG&A 12.91M 12.69M 17.01M 24.81M 32.35M
Other Operating Expense 0 0 0 0 0
Unusual Expense 845,000 2.12M 0 0 0
EBIT after Unusual Expense (845,000) (2.12M) 0 0 0
Non Operating Income/Expense 0 966,967 5,560 14,416 0
Non-Operating Interest Income 97,737 49,015 63,530 59,028 229,229
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 3.27M
Gross Interest Expense 0 0 0 0 3.27M
Interest Capitalized 0 0 0 0 0
Pretax Income (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Minority Interest Expense 0 0 0 0 0
Net Income (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
EPS (Basic) (0.67) (0.56) (0.19) (0.48) (0.74)
Basic Shares Outstanding 86.7M 94.36M 102.57M 111.08M 112.81M
EPS (Diluted) (0.67) (0.56) (0.19) (0.48) (0.74)
Diluted Shares Outstanding 86.7M 94.36M 102.57M 111.08M 112.81M
EBITDA (56.17M) (50.63M) (18.74M) (52.55M) (79.21M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Halozyme Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 13.67M 13.62M 56.09M 42.33M 54.8M
Cost of Goods Sold (COGS) incl. D&A 1.76M 2.49M 1.35M 2.17M 7.47M
COGS excluding D&A 311,891 985,283 257,834 1.09M 6.25M
Depreciation & Amortization Expense 1.44M 1.51M 1.1M 1.08M 1.23M
Depreciation 1.44M 1.51M 1.1M 1.08M 1.23M
Amortization of Intangibles - 0 0 0 0
Gross Income 11.92M 11.13M 54.73M 40.15M 47.33M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 69.53M 63.27M 74.57M 93.78M 127.76M
Research & Development 56.61M 50.57M 57.56M 68.96M 95.41M
Other SG&A 12.91M 12.69M 17.01M 24.81M 32.35M
Other Operating Expense 0 0 0 0 0
Unusual Expense 845,000 2.12M 0 0 0
EBIT after Unusual Expense (845,000) (2.12M) 0 0 0
Non Operating Income/Expense 0 966,967 5,560 14,416 0
Non-Operating Interest Income 97,737 49,015 63,530 59,028 229,229
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 3.27M
Gross Interest Expense 0 0 0 0 3.27M
Interest Capitalized 0 0 0 0 0
Pretax Income (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Minority Interest Expense 0 0 0 0 0
Net Income (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (58.36M) (53.24M) (19.77M) (53.55M) (83.48M)
EPS (Basic) (0.67) (0.56) (0.19) (0.48) (0.74)
Basic Shares Outstanding 86.7M 94.36M 102.57M 111.08M 112.81M
EPS (Diluted) (0.67) (0.56) (0.19) (0.48) (0.74)
Diluted Shares Outstanding 86.7M 94.36M 102.57M 111.08M 112.81M
EBITDA (56.17M) (50.63M) (18.74M) (52.55M) (79.21M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)